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The immune consequences of in utero HIV exposure to uninfected children whose mothers were submitted to highly active
antiretroviral therapy (HAART) during gestation are not well defined. We evaluated 45 HIV-exposed uninfected (ENI) neonates
and 45 healthy unexposed control (CT) neonates. All HIV-infected mothers received HAART during pregnancy, and the viral load
at delivery was <50 copies/mL for 56.8%. Twenty-three ENI neonates were further evaluated after 12 months and compared to
23 unexposed healthy age-matched infants. Immunophenotyping was performed by flow cytometry in cord and peripheral blood.
Cord blood lymphocyte numbers did not differ between groups. However, ENI neonates had a lower percentage of naive T cells
than CT neonates (CD4+, 76.6 vs 83.1%, P < 0.001; CD8+, 70.9 vs 79.6%, P = 0.003) and higher percentages of central memory
T cells than CT neonates (CD4+, 13.9 vs 8.7%, P < 0.001; CD8+, 8.6 vs 4.8%, P = 0.001). CD38 mean fluorescence intensity of
T cells was higher in ENI neonates (CD4+, 62.2 vs 52.1, P = 0.007; CD8+, 47.7 vs 35.3, P < 0.001). At 12 months, ENI infants
still had higher mean fluorescence intensity of CD38 on T cells (CD4+, 34.2 vs 23.3, P < 0.001; CD8+, 26.8 vs 19.4, P = 0.035).
Despite effective maternal virologic control at delivery, HIV-exposed uninfected children were born with lower levels of naive T
cells. Immune activation was present at birth and remained until at least 12 months of age, suggesting that in utero exposure to
HIV causes subtle immune abnormalities.
Key words: Immunophenotyping; Highly active antiretroviral therapy; HIV-1; Immunological stimulation; Neonates of HIV-
infected mothers
Research supported by FAPESP (#01/11011-6) and CAPES.
Received February 25, 2008. Accepted August 4, 2008
Introduction
Worldwide, women account for nearly half of the 40
million people living with HIV/AIDS (1), leading to an esti-
mated two million infants exposed every year to human
immunodeficiency virus type 1 (HIV-1) during pregnancy
and delivery (2).
The use of highly active antiretroviral therapy (HAART)
in resource-rich countries has decreased the vertical trans-
mission of HIV-1 to rates as low as 0.99% (3). However,
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being conceived and undergoing embryonic and fetal de-
velopment in an environment modified by maternal HIV
infection can have consequences that might go beyond
HIV infection itself. A limited number of studies have ad-
dressed this issue (4,5), highlighting the state of immune
activation (4,6) in children born to HIV-infected mothers.
However, in these studies, data were collected from chil-
dren whose mothers had not necessarily received HAART,
the currently accepted antenatal treatment for maternal
HIV infection (3).
In the present study, we evaluated several mono-
nuclear cell parameters of HIV-1-exposed uninfected neo-
nates (ENI) whose mothers were on triple therapy. Using
flow cytometric analyses, we studied cord blood mono-
nuclear cells, including B cells, natural killer (NK) cells,
CD34+ progenitors, CD4+ and CD8+ T subsets, along with
their subpopulations and activation markers, and com-
pared them to those in cord blood from neonates born to
non-HIV-infected healthy control mothers (CT). The same
analysis was performed on a subgroup of the HIV-exposed
uninfected neonates at 12 months of age and the results
were compared to those of healthy non-HIV-exposed in-
fants of the same age.
Our aim was to determine whether non-HIV-infected
children born to HIV-infected women on HAART would
show evidence of immune activation and whether that
state would be demonstrable at 12 months after birth.
Subjects and Methods
Patients and study design
The protocol was approved by the Ethics Committee of
the Federal University of São Paulo. All mothers gave
written informed consent prior to enrollment in the study.
Ninety neonates born in two Maternity Units of the Federal
University of São Paulo were evaluated from March 2004
to October 2005. HIV-1-exposed neonates (ENI neonates,
N = 45) were given formula and not breast-fed. They were
followed-up regularly at the Pediatric AIDS Outpatient
Clinic of the Federal University of São Paulo, Brazil. The
children were considered to be HIV-exposed uninfected if
they had two negative HIV-RNA detection tests, with the
second performed when the infant was 4 months old.
Forty-five healthy term neonates born to HIV-negative
mothers were included in the HIV-negative control neo-
nate group (CT neonates).
The information collected included maternal age at
delivery, maternal antiretroviral treatment, maternal viral
load during pregnancy and at delivery, type of delivery,
neonate birth weight, and gestational age.
Twenty-three of the 45 HIV-1-exposed neonates were
also evaluated at 12 months of age (ENI infants) and were
compared to another 23 healthy non-HIV-exposed infants
of the same age (CT infants). Children from the control
infant group were not part of the control neonate group.
These infants were recruited at an outpatient clinic in São
Paulo where they were part of a routine follow-up program
of healthy infants. They were born at term weighing more
than 2500 g without previous history of serious disease. At
assessment, they did not present any diseases and were
not on any medications.
Neonate subset
Forty-five exposed neonates (one pair of twins) born to
44 HIV-infected women and 45 neonates born to 45 HIV-
negative women were analyzed. All mother-infant pairs
were selected in 2 Maternity Units linked to the Federal
University of São Paulo, and no socio-economical or racial
differences were noted between groups. Mean age of the
HIV-infected mothers was 4.4 years greater than the con-
trol group (HIV: 29.6 years vs CT: 25.2 years, P = 0.001,
t-test). All 44 HIV-infected women received highly active
antiretroviral prophylaxis during gestation, which consisted
of two nucleoside reverse transcriptase inhibitors (NRTI)
and one protease inhibitor in 29/44 (65.9%) of the women
and of two NRTI and one non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) in 15/44 (34.1%) of the women.
Fifteen of the 44 HIV-infected women (34.1%) received
some antiretroviral treatment before pregnancy, which
was modified in order to reduce viral load in some of them
or to avoid toxic drugs, e.g., efavirenz. Twenty-eight of the
44 (63.6%) women reached HIV viral load levels below 400
copies/mL and maintained those levels for 10.7 weeks
(mean) during gestation. Viral load at delivery was below
50 copies/mL in 25 of 44 women (56.8%). Mean viral load
in the other 19 HIV-infected women was 1569.4 copies/
mL. Elective caesarean section was performed in 37 of the
44 HIV-1-positive women and in 3 of the 45 HIV-seronega-
tive women (P < 0.001, chi-square test).
None of the mothers from the control group presented
any infection during pregnancy that could be transmitted
vertically. A total of 5 HIV-infected mothers of the 44
(11.4%) had coinfections during pregnancy: 2 had sero-
logic evidence of syphilis, 1 was hepatitis C (HCV) and
human papillomavirus positive, 1 had genital herpes (HSV)
and 1 had Pneumocystis jiroveci infection and toxoplas-
mosis. All mothers were treated during pregnancy for their
coinfections. Also, neonates born to mothers with syphilis
and toxoplasmosis were evaluated and treated after birth,
without any signs or symptoms of congenital infections.
Neither HCV nor HSV were transmitted to the children.
One child born to an HIV-infected mother with an unevent-
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ful pregnancy but detected viral load at delivery (log 3.8
log/mL) had early sepsis due to Streptococcus viridans,
which resolved after treatment. As for drug addition, 4 of
the 44 (10%) HIV-infected mothers reported use of co-
caine or crack. None of the control mothers reported use of
illicit drugs.
Mean birth weight and mean gestational age were
lower in exposed neonates in comparison to the control
ones (2874.8 vs 3358.1 g and 37.7 vs 39.6 weeks, respec-
tively; P < 0.001 for both analyses, t-test). The characteris-
tics of study subjects are summarized in Table 1.
Infant subset
Twenty-three exposed uninfected infants born to 22
HIV-infected women and 23 matched control infants were
analyzed. Demographic and clinical characteristics were
not different between the groups with respect to age (mean:
12.3 vs 12.4 months; t-test) and gender (65.2% females
among HIV-exposed vs 52.2% females among control
infants; chi-square test).
Blood collection and complete blood count
Cord blood (10 mL) was collected from the umbilical
vein. Twelve-month-old infants had a 5-mL blood sample
collected by peripheral vein access. The blood samples
were put into EDTA-treated vacuum tubes for complete
blood count, phenotypic analysis of peripheral blood mon-
onuclear cell subsets using flow cytometric assays and
plasma IL-7 levels. All samples were tested using Advia
120 automatic counter (Bayer, Ireland) and confirmed by a
slide smear performed for manual count.
Flow cytometry analyses
Peripheral blood mononuclear cells were assessed by
4-color flow cytometry (FACSCalibur, BD Biosciences,
USA) after cell staining using lyse-wash protocol and ana-
lyzed using the CellQuest software (BD Biosciences).
Isotypic controls (IgG1-FITC, IgG1-PE, IgG1-APC, IgG2a-
PE, all from BD Biosciences) were used to evaluate non-
specific staining. The number of cells per cubic milliliter of
blood was obtained using the lymphocyte counts from the
complete blood count.
Cell subsets
CD4+ and CD8+ T lymphocytes. The markers used to
assess the subpopulation within the CD4+ (CD3-APC and
CD4-PerCP labeled) and CD8+ (CD3+ and CD8-PerCP
labeled) populations were CD45RA-FITC and CCR7-PE
(BD Biosciences). In both CD4+ and CD8+ populations,
the naive cells were CD45RA+CCR7+. The “central mem-
ory” cells were CD45RA-CCR7+ and the “effector memo-
ry” cells were CD45RA-CCR7-. The “terminally differenti-
ated memory” cells, more abundantly seen among CD8+
cells than in the CD4+ cohort, were CD45RA+CCR7- (7,8).
CD4+ and CD8+ T lymphocyte activation. Lymphocyte
activation was evaluated by the expression of CD38 on
CD4+ and on CD8+ T cells using two different approaches:
the mean fluorescence intensity of single parameter histo-
grams representing each population and the percentage
of positive cells assessed with the use of isotype controls.
B lymphocytes and NK cells. B lymphocytes were
identified as CD3-CD19+ cells. NK cells were quantified by
the CD45+CD3-CD56+CD16+ phenotype.
Table 1. Characteristics of study subjects.
Characteristic ENI neonates CT neonates
Maternal age in years 29.6 (17-40) 25.2 (15-38)*
Women on HAART prophylaxis (%) 44/44 (100%)
Gestational age in weeks at the introduction of HAART 19.5 (0-36.3)
Gestational age in weeks at first HIV viral load <400 copies/mL 28.2 (1-39.1)
Women who reached viral load <400 copies/mL during pregnancy (%) 28/44 (63.6%)
Weeks of gestation with viral load <400 copies/mL 10.7 (1-35.7)
Women with HIV viral load <50 copies/mL at delivery 25/44 (56.8%)
Viral load in women with >50 copies/mL at delivery 1569.4 (55-5660)
Caesarean section 44/44 (100%) 9/45 (20%)+
Elective caesarean section 37/44 (84.1%) 3/45 (6.7%)+
Birth weight in g 2874.8 (1795-4065) 3358.1 (2825-4050)**
Gestational age in weeks 37.7 (31.1-40.7) 39.6 (37.0-42.0)**
Data are reported as means with range in parentheses or number with percent in parentheses. ENI = HIV-exposed uninfected
neonates (44 mothers and 45 neonates). CT = control healthy neonates (45 mothers and 45 neonates). HAART = highly active
antiretroviral therapy.
*P = 0.01 (t-test), **P < 0.001 (t-test), +P < 0.001 (chi-square test) compared to ENI neonates.
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CD34+ progenitors. Progenitor cells were identified as
CD45+CD34+ cells.
Measurement of plasma IL-7
IL-7 was measured in plasma samples from 21 ex-
posed uninfected neonates, 20 control neonates, 19 chil-
dren from the exposed infant group, and 20 healthy chil-
dren from the control infant group. The test was performed
using a high-sensitivity enzyme-linked immunosorbent
assay kit (Quantikine HS human IL-7; R&D, USA) accord-
ing to manufacturer instructions. The minimum detectable
concentration of IL-7 using this kit is typically 0.1 pg/mL.
Statistical analysis
Group characteristics at study entry were compared
using the t-test or chi-square test. For peripheral blood
leukocytes and phenotype analyses, the t-test was per-
formed. Logarithmic transformation was done when nec-
essary in order to normalize the distribution. Level of
significance was set at P < 0.05.
Results
Neonate subset
Peripheral blood leukocytes. Exposed uninfected neo-
nates had higher lymphocyte and basophil counts than
control neonates but lower hemoglobin concentration, neu-
trophil and monocyte counts. Mean white blood cells,
platelets and eosinophils were similar in the two groups
(Table 2).
CD3+, CD4+ and CD8+ total T cells, B cells, NK cells
and CD45+CD34+ progenitors. No differences were ob-
served between the groups when absolute numbers of
CD3+, CD4+, and CD8+ T cells, B cells, NK cells and
CD45+CD34+ cells were analyzed in neonates (Table 3).
CD4+ and CD8+ T cell subsets. Exposed uninfected
neonates showed higher mean percentages of central
memory CD4+ T (Figure 1A) and central memory CD8+ T
cells (Figure 1B), with lower mean percentages of naive
CD4+ T cells (Figure 1A) and naive CD8+ T cells (Figure
1B).
Table 2. Blood count of HIV-exposed uninfected (ENI) and control healthy (CT) neonates at birth (cord blood) and of infants at 12 months of age.
Parameters Cord blood Peripheral blood (12 months)
ENI neonates (N = 45) CT neonates (N = 45) ENI infants (N = 23) CT infants (N = 23)
White blood cells (cells/mm3) 12,538 (4040-43,060) 13,000 (8200-34,000) 12,700 (6800-25,400) 10,500 (7300-17,100)*
Hemoglobin (g/dL) 14.3 (10.8-18.5) 15.1 (11.2-17.6)* 11.9 (10.4-13.1) 11.5 (9.5-13.6)
Platelets (/mm3) 287,380 (57,000-467,000) 303,500 (113,000-522,000) 469,000 (278,000-694,000) 429,400 (305,000-732,000)
Neutrophils (cells/mm3) 5182 (1620-18,100) 6800 (2900-17,300)** 4600 (1500-8600) 3700 (1900-6500)
Monocytes (cells/mm3) 830 (200-2100) 1000 (500-2700)* 900 (300-1500) 800 (500-1100)
Eosinophils (cells/mm3) 4500 (30-5990) 5000 (40-52,600) 400 (10-15,900) 500 (100-2700)
Basophils (cells/mm3) 274 (30-2440) 100 (40-200)* 20 (0-107) 0 (0-0)*
Lymphocytes (cells/mm3) 6216 (1350-23,250) 4700 (1900-12,900)* 6900 (3700-16,000) 5500 (3400-8900)*
Data are reported as mean and range.
*P < 0.05 and **P < 0.01 compared to ENI neonates (t-test).
Table 3. CD3+, CD4+ and CD8+ total T cells, B cells, natural killer (NK) cells and CD45+CD34+ progenitors in HIV-exposed uninfected (ENI) and in
control healthy (CT) neonates at birth (cord blood) and in infants at 12 months of age.
Subset Cord blood Peripheral blood (12 months)
(cells/mm3)
ENI neonates (N = 45) CT neonates (N = 45) ENI infants (N = 23) CT infants (N = 23)
CD3+ T cells 2235.7 (610.1-7680.7) 1820.3 (531.4-5684.8) 3965.5 (1756.3-7707.0) 3343.5 (1959.4-5320.5)
CD4+ T cells 1448.6 (433.7-3963.4) 1267.1 (236.7-2986.2) 2481.0 (1102.1-4290.8) 1974.5 (1214.3-3671.1)
CD8+ T cells 645.4 (104.9-1823.5) 539.0 (188.1-1728.7) 1181.8 (405.5-2672.0) 1008.7 (562.6-1734.6)
B cells 690.2 (70.4-2404.2) 699.4 (31.2-2175.7) 1806.6 (736.0-6620.8) 1440.9 (791.4-2581.7)
NK cells 1086.5 (101.6-5903.2) 934.7 (268.1-9006.6) 771.0 (110.0-1822.1) 440.8 (143.6-1468.5)*
CD45+CD34+ progenitors 115.9 (4.4-389.6) 113.1 (292.4-5089.8) 18.8 (0.8-50.0) 29.6 (4.8-86.8)
Data are reported as mean and range.
*P < 0.01 compared to ENI neonates (t-test).
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Expression of activation markers on CD4+ and CD8+ T
cells. CD38 expression was statistically higher in the ex-
posed uninfected neonates compared with the controls
(Figure 2A).
CD38 expression evaluated as the percentage of CD38-
positive cells showed similar results for cord CD8+ T cells
(ENI, 92.1 vs CT, 88.2%, P = 0.048, t-test) but the differ-
ence was not statistically significant for cord CD4+ T cells
(ENI, 95.8 vs CT, 93.6%, P = 0.129, t-test).
Plasma IL-7 in neonates. Plasma IL-7 concentrations
were similar in HIV-exposed neonates and healthy neo-
nates (4.2 vs 4.5 pg/mL).
Infant subset
Peripheral blood leukocytes. Mean white blood cells,
lymphocytes and basophils were higher in the HIV-ex-
posed uninfected infants than in the controls. Mean hemo-
globin level, number of platelets, neutrophils, monocytes,
and eosinophils were not different in the two groups of
children (Table 2).
CD3+, CD4+ and CD8+ total T cells, B cells, NK cells
and CD45+CD34+ progenitors. Mean NK cell values were
higher in exposed uninfected infants than in controls. No
statistical differences were observed between the groups
when absolute numbers of CD3+, CD4+, and CD8+ T
Figure 1. CD4+ and CD8+ T cell subsets using CD45RA and CCR7 markers in HIV-exposed uninfected (ENI) and in control healthy
(CT) neonates at birth (cord blood) and in infants at 12 months of age. A, CD4+ T cell subset in 45 HIV-exposed uninfected neonates
and in 45 control healthy neonates. B, CD8+ T cell subset in 45 HIV-exposed uninfected neonates and in 45 control healthy neonates.
C, CD4+ T cell subset at 12 months of age in 23 HIV-exposed uninfected infants and in 23 control healthy infants. D, CD8+ T cell
subset at 12 months of age in 23 HIV-exposed uninfected infants and in 23 control healthy infants. Horizontal lines in box plots indicate
the 25th, 50th, and 75th percentiles; top and bottom vertical lines mark extreme values and, when present, the small circles represent
outlying values. The t-test was used for statistical analysis.
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cells, B cells and CD45+CD34+ progenitors were ana-
lyzed (Table 3). However, mean CD3+ T cells (3965.5 vs
3343.5 cells/mm3, P = 0.080, t-test) and CD4+ T cells
(2481.0 vs 1974.5 cells/mm3, P = 0.072, t-test) showed a
trend to higher numbers in exposed infants. By contrast,
CD45+CD34+ progenitors showed an opposite trend, with
higher values in control infants (18.8 vs 29.6 cells/mm3, P
= 0.061, t-test).
CD4+ and CD8+ T cell subsets. Exposed uninfected
infants showed significantly higher mean percentages of
naive CD4+ T cells, with lower mean percentages of termi-
nally differentiated CD4+ T cells (Figure 1C). Mean per-
centages of naive CD8+ T cells were also higher in the
exposed uninfected infants with lower mean percentages
of terminally differentiated CD8+ T cells (Figure 1D). The
percentages of central and effector memory cells were
similar between both groups for both CD4+ T cells (Figure
1C) and CD8+ T cells (Figure 1D).
Expression of activation markers on CD4+ and CD8+ T
cells. CD38 expression was significantly higher on CD4+ T
cells from exposed uninfected infants compared to the
controls. CD38 expression on CD8+ T cells was also
higher in exposed uninfected children than in the controls
(Figure 2B).
Similar to that which was observed for cord blood,
peripheral CD38+CD4+ T cells (ENI, 83.4 vs CT, 74.3%, P
= 0.004, t-test) and CD38+CD8+ T cells (ENI, 83.4 vs CT,
63.2%, P = 0.010, t-test) were more prevalent in ENI
children at 12 months of age when compared to CT infants.
Plasma IL-7 in children at 12 months of age. Plasma IL-
7 concentrations were significantly lower in the HIV-ex-
posed children at 12 months of age compared to the
control infants at 12 months of age (5.2 vs 6.8 pg/mL, P =
0.012, t-test).
Discussion
In 2000, Clerici et al. (4) described an increased ex-
pression of immune activation markers in 20 HIV-exposed
uninfected infants compared with 14 healthy HIV-non-
exposed infants. They suggested that those findings could
be explained by the exposure to HIV in utero.
In the present study, analyzing a population more than
twice as large as Clerici’s, we looked for similar immune
parameter changes in ENI born to HIV-infected mothers
treated with state-of-the-art interventions to prevent mother-
to-child transmission of HIV. Our results demonstrate that,
despite adequate prophylaxis, these neonates still pre-
sented a different immunologic profile of CD4+ and CD8+
T cells when compared to neonates born to HIV-uninfected
mothers, with a shift from naive to memory/effector pheno-
types and higher activation by CD38 expression. At 12
months of age, HIV-1-exposed infants maintained an up-
regulation of CD38.
In HIV-exposed uninfected neonates, lower birth weight
and smaller gestational age could be related to the higher
rates of elective cesarean section in this group (9,10).
However, anti-retroviral drugs prescribed to the mothers
might have also contributed. The same observations have
been reported by Briand et al. (11).
HIV-exposed uninfected children had lower hemoglo-
bin levels, less neutrophils and monocytes, and higher
basophils and lymphocytes at birth. Lower hemoglobin
levels and neutropenia (12,13) have been shown previ-
ously in infants exposed in utero to antiretroviral drugs. In
a recent publication, different antiretroviral schemes led to
diverse toxic effects (14). In our study, hemoglobin levels
Figure 2. Mean fluorescence intensity of CD38+ in CD4+ and
CD8+ T cells in HIV-exposed uninfected (ENI) and in control
healthy children (CT) at birth (cord blood) and at 12 months of
age. A, CD4+ and CD8+ T cells in HIV-exposed ENI and in CT
neonates. B, CD4+ and CD8+ T cells at 12 months of age in HIV-
exposed ENI and in CT infants. The box plot is described in the
legend to Figure 1. The t-test was used for statistical analysis.
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and neutrophils were similar in the groups at 12 months.
Basophils were higher in HIV-exposed neonates, which
persisted until 12 months of age in our group. Zaccarelli-
Filho et al. (15) have also reported high basophil numbers
in HIV-infected children. These cells are known to be
elevated in conditions associated with Th2 responses
(16). In fact, it has been suggested that HIV infection could
drive the immune system to a humoral response (16,17). In
the same way, HIV-exposed neonates and infants might
manifest a Th2 response.
The presence of a low percentage of naive T cells and
a high percentage of central memory T cells, with a high
CD38 expression, suggests that there may have been
exposure of the fetal immune system to HIV antigens in
utero. Despite the low or even undetectable viral load
levels observed in HIV-1-infected mothers at delivery,
these infants may have been previously exposed to the
virus during their fetal life, resulting in premature activation
and differentiation of T cells.
In fact, only 63.6% of HIV-infected women in our study
attained and maintained a viral load below 400 copies/mL
during gestation. Of those who reached low HIV viral load
levels, the mean period was for 10.7 weeks, which unques-
tionably contributed to the lack of in utero HIV infection.
However, low viral load levels during the last 10 weeks of
pregnancy might have not been enough to avoid antigenic
exposure and its immunologic consequences.
Previous studies by our group and others in perinatal
HIV-exposed infants have reported evidence of HIV-spe-
cific immune response (4,18-25). HIV-specific immune
response has also been observed in exposed noninfected
adults (26-29).
Interestingly, Schenal et al. (30) showed that whereas
HIV-exposed uninfected adults had high central memory
HIV-specific cells, HIV-infected patients had higher levels
of the HIV-specific effector memory subset. A predomi-
nance of central memory over effector memory percent-
ages was observed for total T cells in our study. Schenal et
al. concluded that the same immunologic stimuli/signals
that lead to prolonged immune activation in HIV-seroposi-
tive patients also occurred in exposed uninfected individu-
als. However, low viral load exposure could lead to higher
central memory percentages.
In the present study, despite only being exposed to HIV
up to delivery, infants still maintained upregulated immune
activation markers at 12 months of age, along with high
numbers of NK cells. NK cells are members of the innate
immune system and increased interferon-γ production by
these cells has been found in HIV-exposed uninfected
adults (31). On the other hand, low NK cell numbers have
been linked to progression to HIV disease (32,33). There-
fore, it is possible that NK cells might have had a protective
role in avoiding infection in HIV-1-exposed infants.
In contrast to Clerici et al. (4), we did not find high IL-7
plasma levels in HIV-exposed neonates. Moreover, the
fact that those children at 12 months of age had a tendency
to present higher CD4+ T cells might have contributed to
lower IL-7 plasma levels at that age in comparison to non-
HIV-exposed controls.
HIV-1-exposed infants still had different immunologic
parameters at 12 months of age, although higher naive
CD4+ and CD8+ T cells were an unexpected finding. In the
same way that HIV-infected children who respond to HAART
increase the naive subset of T cells (34-36), it is possible
that no further HIV exposure after birth might lead to
reduction in the proportion of central memory CD4+ and
CD8+ T cells and, as a consequence, an increase in naive
T cells in children born to HIV-1-infected mothers.
However, it is not possible to clearly ascertain whether
some abnormalities have resulted from the antiretroviral
drug exposure during pregnancy. Moreover, another pos-
sibility that might be considered is the altered maternal
immune environment, which, per se, could have contrib-
uted to the findings.
In conclusion, we have shown that HIV-exposed un-
infected children present many differences in cellular im-
mune parameters at birth that persist at least for one year.
Among those, a state of immune activation is probably the
most striking and might have consequences not always
immediately identified, but may result in distinct immune
responses, including those to vaccine antigens previously
reported by our group (37) and by others (6), with a higher
humoral immune response to rubella (37) and lower cellu-
lar response to BCG (6). Some have even linked the state
of immune activation, even more so than the viral load, to
the destruction of CD4+ T cells and progression to AIDS in
children (38) and adults (39). Further studies must address
whether these findings could have an impact on the cellu-
lar immune responses to self and foreign antigens and
result in clinical consequences to children born to HIV-1-
infected mothers.
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